Omalizumab, a monoclonal antibody targeting IgE, administered subcutaneously and approved for allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyps, acts by binding circulating IgE, preventing it from interacting with FcεRI on mast cells and basophils, thereby reducing allergic responses and mast cell degranulation. This evidence concerns the gene IGHE and allergic asthma.